← Book Three · The American Supplement Investigation
Book Three · The Reckoning

Prove It

Chronic disease claims, misinformation, and what should change

The trilogy's closing volume applies Books One and Two to the questions that actually bring people to a supplement aisle: can anything here meaningfully affect a real chronic disease? Why does confident misinformation consistently beat careful evidence for attention? And when the claims meet real, documented cases — an FDA-banned stimulant, a red yeast rice product litigated for years, a longevity compound caught in a regulatory reversal — what does the evidence actually show? The book closes with an appendix proposing a specific, tiered framework for what U.S. supplement regulation should look like.

Read the Full Book Read the investigation
Joy Meier, Pharm.D. and Robert Coleman, MS Pharm. · Coleman Publishing
Cover of Prove It
The Investigation

What This Book Is About

Books One and Two built two toolkits — how to evaluate a health claim, and how the regulatory and business system around supplements actually works. This book applies both to the hardest material in the investigation: real diagnoses, a real information ecosystem, and real documented cases.

Every chronic disease claim in this book is evaluated the same way: Claim → Biological rationale → Evidence → Clinical outcome → Risk → Bottom line — the same framework, run consistently, so a reader can apply it independently long after finishing the book.

25,871Participants in the VITAL trial testing omega-3 and vitamin D for cardiovascular disease and cancer prevention
3,069Participants in the largest trial ever run on ginkgo biloba for dementia prevention — a clean negative result
4Fully documented, sourced case files — from an FDA ban to a 2025 regulatory reversal

The Great Supplement Questions

Fish oil shows a real, narrower cardiovascular benefit than marketed. Ginkgo biloba shows none at all for dementia, in the largest trial ever run on the question. Calcium and vitamin D are this book's deliberate exception — a real, replicated benefit for fracture risk, with a genuine cardiovascular caveat attached. Five conditions, one recurring shape: a plausible mechanism, a real trial, and a result narrower than the label implies.

The Information Problem

A rigorous trial takes years and tens of millions of dollars. A confident video contradicting it takes an afternoon. This book explains why platforms structurally reward confident claims over accurate ones, why misinformation functions as a business model rather than a side effect for some publishers, and why intelligence — contrary to what most people assume — offers surprisingly little protection against believing a claim that isn't true.

"Intelligence helps you construct a more sophisticated justification for a belief. It does not reliably protect you from forming the belief incorrectly in the first place."Prove It

Case Files

Four fully documented cases: the ephedra ban that followed a young athlete's death, a red yeast rice product litigated through the federal appeals courts, a persistent FDA enforcement pattern against tainted sexual-enhancement products, and a 2022–2025 regulatory reversal over a popular longevity compound — chosen deliberately to show that regulatory failure runs in more than one direction.

Inside the Book

Eleven Chapters, Four Parts, One Appendix

Part VII

The Great Supplement Questions

Chronic disease, vitamins, minerals, herbal remedies, and a rapid tour of ten marketed promises — weight loss to anti-aging.

Parts VIII–IX

The Information Problem & International Perspective

Why science loses to content, the misinformation business, why smart people believe — and what Canada, Australia, the EU, and the UK do differently.

Part X

Case Files & Following the Evidence

Four documented cases and a closing synthesis of the entire trilogy's findings, book by book.

The Trilogy's Recommendation

What Should Change

A tiered evidence framework for U.S. supplement regulation, modeled on what's already working in Canada and Australia — not a demand to ban a category, and not the status quo. The appendix that closes this investigation.

Read the appendix
← Book Two: The Hollow Aisle